ERBB2 and breast cancer: Additionally, both TRPM4 frequency (median cut-off) and intensity (negative/weak vs moderate/strong) were not associated with all pathological parameters investigated i. e. estrogen receptor (ER), progesterone receptor (PR), human growth factor receptor-2 (HER2), breast cancer subtype and Ki-67 (Table 1).